These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 9536083)

  • 1. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim.
    Bar-Sade RB; Kruglikova A; Modan B; Gak E; Hirsh-Yechezkel G; Theodor L; Novikov I; Gershoni-Baruch R; Risel S; Papa MZ; Ben-Baruch G; Friedman E
    Hum Mol Genet; 1998 May; 7(5):801-5. PubMed ID: 9536083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.
    Laitman Y; Feng BJ; Zamir IM; Weitzel JN; Duncan P; Port D; Thirthagiri E; Teo SH; Evans G; Latif A; Newman WG; Gershoni-Baruch R; Zidan J; Shimon-Paluch S; Goldgar D; Friedman E
    Eur J Hum Genet; 2013 Feb; 21(2):212-6. PubMed ID: 22763381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Could the 185delAG BRCA1 mutation be an ancient Jewish mutation?
    Bar-Sade RB; Theodor L; Gak E; Kruglikova A; Hirsch-Yechezkel G; Modan B; Kuperstein G; Seligsohn U; Rechavi G; Friedman E
    Eur J Hum Genet; 1997; 5(6):413-6. PubMed ID: 9450187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tyr978X BRCA1 mutation: occurrence in non-Jewish Iranians and haplotype in French-Canadian and non-Ashkenazi Jews.
    Quintana-Murci L; Gal I; Bakhan T; Quach H; Sayar SH; Shiri-Sverdlov R; Baruch RG; McElreavey K; Dagan E; Narod S; Friedman E
    Fam Cancer; 2005; 4(2):85-8. PubMed ID: 15951957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
    Berman DB; Wagner-Costalas J; Schultz DC; Lynch HT; Daly M; Godwin AK
    Am J Hum Genet; 1996 Jun; 58(6):1166-76. PubMed ID: 8651293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews.
    Theodor L; Bar-Sade R; Kruglikova A; Ben-Baruch G; Risel S; Shiri-Sverdlov R; Hirsh Yechezkel G; Modan B; Papa MZ; Rechavi G; Friedman E
    Br J Cancer; 1998 Jun; 77(11):1880-3. PubMed ID: 9667663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
    Laitman Y; Simeonov M; Herskovitz L; Kushnir A; Shimon-Paluch S; Kaufman B; Zidan J; Friedman E
    Breast Cancer Res Treat; 2012 Jun; 133(3):1153-7. PubMed ID: 22399190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data.
    Bahar AY; Taylor PJ; Andrews L; Proos A; Burnett L; Tucker K; Friedlander M; Buckley MF
    Cancer; 2001 Jul; 92(2):440-5. PubMed ID: 11466700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
    Lee JS; Wacholder S; Struewing JP; McAdams M; Pee D; Brody LC; Tucker MA; Hartge P
    J Natl Cancer Inst; 1999 Feb; 91(3):259-63. PubMed ID: 10037104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRCA1 Ashkenazi founder mutations occur on common haplotypes and are not highly correlated with anonymous single nucleotide polymorphisms likely to be used in genome-wide case-control association studies.
    Pereira LH; Pineda MA; Rowe WH; Fonseca LR; Greene MH; Offit K; Ellis NA; Zhang J; Collins A; Struewing JP
    BMC Genet; 2007 Oct; 8():68. PubMed ID: 17916242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals.
    Struewing JP; Abeliovich D; Peretz T; Avishai N; Kaback MM; Collins FS; Brody LC
    Nat Genet; 1995 Oct; 11(2):198-200. PubMed ID: 7550349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.